nodes	percent_of_prediction	percent_of_DWPC	metapath
Everolimus—CYP3A4—Fluticasone furoate—asthma	0.041	0.0796	CbGbCtD
Everolimus—CYP3A4—Budesonide—asthma	0.0365	0.0709	CbGbCtD
Everolimus—CYP3A4—Ciclesonide—asthma	0.0334	0.0649	CbGbCtD
Everolimus—CYP3A4—Indacaterol—asthma	0.0334	0.0649	CbGbCtD
Everolimus—CYP3A4—Salmeterol—asthma	0.031	0.0603	CbGbCtD
Everolimus—CYP3A4—Salbutamol—asthma	0.031	0.0603	CbGbCtD
Everolimus—CYP3A4—Flunisolide—asthma	0.031	0.0603	CbGbCtD
Everolimus—CYP3A4—Zileuton—asthma	0.0277	0.0538	CbGbCtD
Everolimus—CYP3A4—Ipratropium bromide—asthma	0.0277	0.0538	CbGbCtD
Everolimus—CYP3A4—Fluticasone Propionate—asthma	0.0264	0.0513	CbGbCtD
Everolimus—CYP3A4—Zafirlukast—asthma	0.0244	0.0473	CbGbCtD
Everolimus—CYP3A4—Tiotropium—asthma	0.021	0.0407	CbGbCtD
Everolimus—CYP3A4—Aminophylline—asthma	0.02	0.0389	CbGbCtD
Everolimus—CYP3A4—Theophylline—asthma	0.0188	0.0365	CbGbCtD
Everolimus—CYP3A4—Loratadine—asthma	0.0178	0.0346	CbGbCtD
Everolimus—CYP3A4—Montelukast—asthma	0.0178	0.0346	CbGbCtD
Everolimus—CYP3A4—Methylprednisolone—asthma	0.0163	0.0317	CbGbCtD
Everolimus—CYP3A4—Triamcinolone—asthma	0.0124	0.024	CbGbCtD
Everolimus—CYP3A4—Betamethasone—asthma	0.0106	0.0206	CbGbCtD
Everolimus—CYP3A4—Prednisolone—asthma	0.0105	0.0203	CbGbCtD
Everolimus—CYP3A4—Hydrocortisone—asthma	0.00992	0.0193	CbGbCtD
Everolimus—CYP3A4—Prednisone—asthma	0.00988	0.0192	CbGbCtD
Everolimus—CYP3A4—Dexamethasone—asthma	0.00617	0.012	CbGbCtD
Everolimus—MTOR—respiratory system—asthma	0.00351	0.0927	CbGeAlD
Everolimus—FKBP1A—respiratory system—asthma	0.00316	0.0834	CbGeAlD
Everolimus—MTOR—epithelium—asthma	0.00294	0.0775	CbGeAlD
Everolimus—MTOR—smooth muscle tissue—asthma	0.00283	0.0746	CbGeAlD
Everolimus—MTOR—cardiovascular system—asthma	0.00269	0.071	CbGeAlD
Everolimus—FKBP1A—adrenal cortex—asthma	0.00265	0.07	CbGeAlD
Everolimus—FKBP1A—epithelium—asthma	0.00264	0.0697	CbGeAlD
Everolimus—FKBP1A—bronchus—asthma	0.0026	0.0686	CbGeAlD
Everolimus—FKBP1A—smooth muscle tissue—asthma	0.00254	0.0671	CbGeAlD
Everolimus—FKBP1A—cardiovascular system—asthma	0.00242	0.0638	CbGeAlD
Everolimus—FKBP1A—trachea—asthma	0.00234	0.0616	CbGeAlD
Everolimus—MTOR—adrenal gland—asthma	0.00213	0.0561	CbGeAlD
Everolimus—FKBP1A—adrenal gland—asthma	0.00191	0.0505	CbGeAlD
Everolimus—MTOR—lung—asthma	0.00187	0.0492	CbGeAlD
Everolimus—FKBP1A—lung—asthma	0.00168	0.0443	CbGeAlD
Everolimus—FKBP1A—Signaling Pathways—IL5—asthma	4.91e-05	0.000378	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PARP1—asthma	4.91e-05	0.000378	CbGpPWpGaD
Everolimus—MTOR—Immune System—TLR3—asthma	4.9e-05	0.000378	CbGpPWpGaD
Everolimus—MTOR—Disease—DCN—asthma	4.89e-05	0.000377	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—EGFR—asthma	4.89e-05	0.000376	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—IL6—asthma	4.87e-05	0.000375	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—IL6—asthma	4.79e-05	0.000369	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—PPP2CA—asthma	4.74e-05	0.000365	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—C3—asthma	4.74e-05	0.000365	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—BDKRB2—asthma	4.74e-05	0.000365	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PPP2CA—asthma	4.72e-05	0.000364	CbGpPWpGaD
Everolimus—FKBP1A—Disease—CCR5—asthma	4.64e-05	0.000357	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—PTEN—asthma	4.62e-05	0.000356	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—PDGFB—asthma	4.61e-05	0.000355	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—ADCY2—asthma	4.59e-05	0.000353	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—IL6—asthma	4.57e-05	0.000352	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IL3—asthma	4.57e-05	0.000352	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—C3—asthma	4.55e-05	0.000351	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—IL6—asthma	4.55e-05	0.000351	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—IL6—asthma	4.53e-05	0.000349	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PDE4A—asthma	4.52e-05	0.000348	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—KIF3A—asthma	4.52e-05	0.000348	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—CRP—asthma	4.51e-05	0.000347	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—IL6—asthma	4.51e-05	0.000347	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—VEGFA—asthma	4.45e-05	0.000343	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—PDGFB—asthma	4.43e-05	0.000341	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PDGFB—asthma	4.41e-05	0.00034	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—STAT3—asthma	4.41e-05	0.00034	CbGpPWpGaD
Everolimus—MTOR—Immune System—CYBA—asthma	4.36e-05	0.000336	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL1RN—asthma	4.36e-05	0.000336	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—TLR4—asthma	4.32e-05	0.000333	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—KNG1—asthma	4.31e-05	0.000332	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—AGTR1—asthma	4.29e-05	0.00033	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL5—asthma	4.27e-05	0.000329	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—IL6—asthma	4.24e-05	0.000327	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—IL6—asthma	4.24e-05	0.000327	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—IL6—asthma	4.24e-05	0.000327	CbGpPWpGaD
Everolimus—MTOR—Immune System—HLA-DPB1—asthma	4.24e-05	0.000326	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CYSLTR1—asthma	4.23e-05	0.000326	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—IL6—asthma	4.2e-05	0.000324	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CXCL10—asthma	4.19e-05	0.000323	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—IL6—asthma	4.16e-05	0.000321	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—HLA-DRB1—asthma	4.15e-05	0.000319	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—IL6—asthma	4.15e-05	0.000319	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—STAT3—asthma	4.13e-05	0.000318	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—NTRK1—asthma	4.11e-05	0.000316	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—VIP—asthma	4.09e-05	0.000315	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—C5AR1—asthma	4.09e-05	0.000315	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CCL11—asthma	4.09e-05	0.000315	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CMA1—asthma	4.09e-05	0.000315	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—UTS2—asthma	4.09e-05	0.000315	CbGpPWpGaD
Everolimus—Hallucination—Prednisone—asthma	4.08e-05	0.000129	CcSEcCtD
Everolimus—CYP3A4—Biological oxidations—GSTP1—asthma	4.08e-05	0.000314	CbGpPWpGaD
Everolimus—Malaise—Triamcinolone—asthma	4.08e-05	0.000128	CcSEcCtD
Everolimus—MTOR—Immune System—TLR2—asthma	4.08e-05	0.000314	CbGpPWpGaD
Everolimus—MTOR—Immune System—CD40—asthma	4.08e-05	0.000314	CbGpPWpGaD
Everolimus—Anxiety—Hydrocortisone—asthma	4.07e-05	0.000128	CcSEcCtD
Everolimus—Malaise—Methylprednisolone—asthma	4.07e-05	0.000128	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—ADRB2—asthma	4.07e-05	0.000313	CbGpPWpGaD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—asthma	4.06e-05	0.000128	CcSEcCtD
Everolimus—Syncope—Triamcinolone—asthma	4.05e-05	0.000128	CcSEcCtD
Everolimus—Syncope—Methylprednisolone—asthma	4.04e-05	0.000127	CcSEcCtD
Everolimus—Discomfort—Hydrocortisone—asthma	4.04e-05	0.000127	CcSEcCtD
Everolimus—Connective tissue disorder—Prednisone—asthma	4.03e-05	0.000127	CcSEcCtD
Everolimus—MTOR—Disease—CYBA—asthma	4.03e-05	0.00031	CbGpPWpGaD
Everolimus—Nausea—Budesonide—asthma	4.02e-05	0.000127	CcSEcCtD
Everolimus—CYP3A4—Metapathway biotransformation—GSTP1—asthma	4.02e-05	0.00031	CbGpPWpGaD
Everolimus—MTOR—Immune System—CTLA4—asthma	4.02e-05	0.000309	CbGpPWpGaD
Everolimus—Oedema—Prednisolone—asthma	4.01e-05	0.000126	CcSEcCtD
Everolimus—MTOR—Immune System—ADCY2—asthma	3.99e-05	0.000307	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—ICAM1—asthma	3.98e-05	0.000307	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL3—asthma	3.97e-05	0.000306	CbGpPWpGaD
Everolimus—Loss of consciousness—Triamcinolone—asthma	3.97e-05	0.000125	CcSEcCtD
Everolimus—Loss of consciousness—Methylprednisolone—asthma	3.96e-05	0.000125	CcSEcCtD
Everolimus—Shock—Prednisolone—asthma	3.95e-05	0.000124	CcSEcCtD
Everolimus—MTOR—Disease—PARP1—asthma	3.94e-05	0.000304	CbGpPWpGaD
Everolimus—Cough—Triamcinolone—asthma	3.94e-05	0.000124	CcSEcCtD
Everolimus—FKBP1A—Disease—NOS2—asthma	3.93e-05	0.000303	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CCR4—asthma	3.92e-05	0.000302	CbGpPWpGaD
Everolimus—Oedema—Hydrocortisone—asthma	3.92e-05	0.000123	CcSEcCtD
Everolimus—Convulsion—Triamcinolone—asthma	3.92e-05	0.000123	CcSEcCtD
Everolimus—Tachycardia—Prednisolone—asthma	3.92e-05	0.000123	CcSEcCtD
Everolimus—Convulsion—Methylprednisolone—asthma	3.91e-05	0.000123	CcSEcCtD
Everolimus—Hypertension—Triamcinolone—asthma	3.9e-05	0.000123	CcSEcCtD
Everolimus—Hypertension—Methylprednisolone—asthma	3.89e-05	0.000123	CcSEcCtD
Everolimus—Infection—Hydrocortisone—asthma	3.89e-05	0.000123	CcSEcCtD
Everolimus—Hyperhidrosis—Prednisolone—asthma	3.88e-05	0.000122	CcSEcCtD
Everolimus—Shock—Hydrocortisone—asthma	3.85e-05	0.000121	CcSEcCtD
Everolimus—Myalgia—Triamcinolone—asthma	3.85e-05	0.000121	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—ITPR1—asthma	3.85e-05	0.000296	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—STAT6—asthma	3.84e-05	0.000296	CbGpPWpGaD
Everolimus—Nervous system disorder—Hydrocortisone—asthma	3.84e-05	0.000121	CcSEcCtD
Everolimus—Arthralgia—Methylprednisolone—asthma	3.84e-05	0.000121	CcSEcCtD
Everolimus—Myalgia—Methylprednisolone—asthma	3.84e-05	0.000121	CcSEcCtD
Everolimus—Eye disorder—Prednisone—asthma	3.83e-05	0.000121	CcSEcCtD
Everolimus—MTOR—Immune System—CD79A—asthma	3.83e-05	0.000295	CbGpPWpGaD
Everolimus—Anxiety—Methylprednisolone—asthma	3.83e-05	0.000121	CcSEcCtD
Everolimus—Tachycardia—Hydrocortisone—asthma	3.82e-05	0.00012	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—asthma	3.81e-05	0.00012	CcSEcCtD
Everolimus—Flushing—Prednisone—asthma	3.81e-05	0.00012	CcSEcCtD
Everolimus—Skin disorder—Hydrocortisone—asthma	3.81e-05	0.00012	CcSEcCtD
Everolimus—Ill-defined disorder—Dexamethasone—asthma	3.81e-05	0.00012	CcSEcCtD
Everolimus—Ill-defined disorder—Betamethasone—asthma	3.81e-05	0.00012	CcSEcCtD
Everolimus—Discomfort—Triamcinolone—asthma	3.8e-05	0.00012	CcSEcCtD
Everolimus—Discomfort—Methylprednisolone—asthma	3.79e-05	0.000119	CcSEcCtD
Everolimus—Hyperhidrosis—Hydrocortisone—asthma	3.79e-05	0.000119	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—IL2RB—asthma	3.77e-05	0.000291	CbGpPWpGaD
Everolimus—Dry mouth—Triamcinolone—asthma	3.76e-05	0.000119	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—EGFR—asthma	3.76e-05	0.000289	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—IL6—asthma	3.76e-05	0.000289	CbGpPWpGaD
Everolimus—Angioedema—Dexamethasone—asthma	3.75e-05	0.000118	CcSEcCtD
Everolimus—Angioedema—Betamethasone—asthma	3.75e-05	0.000118	CcSEcCtD
Everolimus—CYP3A4—Biological oxidations—GSTM1—asthma	3.75e-05	0.000289	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PDE4D—asthma	3.74e-05	0.000288	CbGpPWpGaD
Everolimus—Anorexia—Hydrocortisone—asthma	3.73e-05	0.000118	CcSEcCtD
Everolimus—Angiopathy—Prednisone—asthma	3.72e-05	0.000117	CcSEcCtD
Everolimus—MTOR—Disease—NOS1—asthma	3.71e-05	0.000286	CbGpPWpGaD
Everolimus—Immune system disorder—Prednisone—asthma	3.71e-05	0.000117	CcSEcCtD
Everolimus—Malaise—Betamethasone—asthma	3.7e-05	0.000116	CcSEcCtD
Everolimus—Malaise—Dexamethasone—asthma	3.7e-05	0.000116	CcSEcCtD
Everolimus—MTOR—Innate Immune System—IL6R—asthma	3.7e-05	0.000285	CbGpPWpGaD
Everolimus—CYP3A4—Metapathway biotransformation—GSTM1—asthma	3.69e-05	0.000285	CbGpPWpGaD
Everolimus—Oedema—Triamcinolone—asthma	3.69e-05	0.000116	CcSEcCtD
Everolimus—MTOR—Disease—ADCY2—asthma	3.68e-05	0.000284	CbGpPWpGaD
Everolimus—Syncope—Dexamethasone—asthma	3.68e-05	0.000116	CcSEcCtD
Everolimus—Syncope—Betamethasone—asthma	3.68e-05	0.000116	CcSEcCtD
Everolimus—MTOR—Immune System—CD14—asthma	3.67e-05	0.000283	CbGpPWpGaD
Everolimus—Infection—Triamcinolone—asthma	3.66e-05	0.000115	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—CD86—asthma	3.66e-05	0.000282	CbGpPWpGaD
Everolimus—Hypotension—Hydrocortisone—asthma	3.66e-05	0.000115	CcSEcCtD
Everolimus—Infection—Methylprednisolone—asthma	3.66e-05	0.000115	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—C5—asthma	3.64e-05	0.000281	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PDE4B—asthma	3.64e-05	0.000281	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TACR1—asthma	3.64e-05	0.000281	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—EDN1—asthma	3.63e-05	0.00028	CbGpPWpGaD
Everolimus—Shock—Triamcinolone—asthma	3.63e-05	0.000114	CcSEcCtD
Everolimus—Insomnia—Prednisolone—asthma	3.63e-05	0.000114	CcSEcCtD
Everolimus—Alopecia—Prednisone—asthma	3.63e-05	0.000114	CcSEcCtD
Everolimus—Shock—Methylprednisolone—asthma	3.62e-05	0.000114	CcSEcCtD
Everolimus—Nervous system disorder—Methylprednisolone—asthma	3.61e-05	0.000114	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—CCL5—asthma	3.6e-05	0.000278	CbGpPWpGaD
Everolimus—Loss of consciousness—Dexamethasone—asthma	3.6e-05	0.000114	CcSEcCtD
Everolimus—Loss of consciousness—Betamethasone—asthma	3.6e-05	0.000114	CcSEcCtD
Everolimus—Paraesthesia—Prednisolone—asthma	3.6e-05	0.000113	CcSEcCtD
Everolimus—Tachycardia—Triamcinolone—asthma	3.6e-05	0.000113	CcSEcCtD
Everolimus—Mental disorder—Prednisone—asthma	3.59e-05	0.000113	CcSEcCtD
Everolimus—Tachycardia—Methylprednisolone—asthma	3.59e-05	0.000113	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—PLA2G4A—asthma	3.59e-05	0.000277	CbGpPWpGaD
Everolimus—Skin disorder—Methylprednisolone—asthma	3.58e-05	0.000113	CcSEcCtD
Everolimus—Malnutrition—Prednisone—asthma	3.57e-05	0.000112	CcSEcCtD
Everolimus—Erythema—Prednisone—asthma	3.57e-05	0.000112	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Hydrocortisone—asthma	3.57e-05	0.000112	CcSEcCtD
Everolimus—Hyperhidrosis—Triamcinolone—asthma	3.57e-05	0.000112	CcSEcCtD
Everolimus—Hyperhidrosis—Methylprednisolone—asthma	3.56e-05	0.000112	CcSEcCtD
Everolimus—Convulsion—Betamethasone—asthma	3.55e-05	0.000112	CcSEcCtD
Everolimus—Convulsion—Dexamethasone—asthma	3.55e-05	0.000112	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—CSF2—asthma	3.55e-05	0.000274	CbGpPWpGaD
Everolimus—MTOR—Immune System—VCAM1—asthma	3.55e-05	0.000273	CbGpPWpGaD
Everolimus—Insomnia—Hydrocortisone—asthma	3.54e-05	0.000112	CcSEcCtD
Everolimus—Hypertension—Dexamethasone—asthma	3.54e-05	0.000112	CcSEcCtD
Everolimus—Hypertension—Betamethasone—asthma	3.54e-05	0.000112	CcSEcCtD
Everolimus—MTOR—Immune System—HLA-DQA1—asthma	3.54e-05	0.000272	CbGpPWpGaD
Everolimus—FKBP1A—Disease—IL6R—asthma	3.54e-05	0.000272	CbGpPWpGaD
Everolimus—Paraesthesia—Hydrocortisone—asthma	3.52e-05	0.000111	CcSEcCtD
Everolimus—Myalgia—Dexamethasone—asthma	3.49e-05	0.00011	CcSEcCtD
Everolimus—Myalgia—Betamethasone—asthma	3.49e-05	0.00011	CcSEcCtD
Everolimus—Anxiety—Dexamethasone—asthma	3.48e-05	0.00011	CcSEcCtD
Everolimus—Anxiety—Betamethasone—asthma	3.48e-05	0.00011	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—SMAD3—asthma	3.46e-05	0.000266	CbGpPWpGaD
Everolimus—Discomfort—Betamethasone—asthma	3.45e-05	0.000109	CcSEcCtD
Everolimus—Discomfort—Dexamethasone—asthma	3.45e-05	0.000109	CcSEcCtD
Everolimus—Dyspepsia—Hydrocortisone—asthma	3.45e-05	0.000109	CcSEcCtD
Everolimus—Hypotension—Methylprednisolone—asthma	3.44e-05	0.000108	CcSEcCtD
Everolimus—Pain—Prednisolone—asthma	3.43e-05	0.000108	CcSEcCtD
Everolimus—Decreased appetite—Hydrocortisone—asthma	3.41e-05	0.000107	CcSEcCtD
Everolimus—Gastrointestinal disorder—Hydrocortisone—asthma	3.38e-05	0.000107	CcSEcCtD
Everolimus—Fatigue—Hydrocortisone—asthma	3.38e-05	0.000106	CcSEcCtD
Everolimus—Vision blurred—Prednisone—asthma	3.37e-05	0.000106	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Triamcinolone—asthma	3.36e-05	0.000106	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Methylprednisolone—asthma	3.35e-05	0.000106	CcSEcCtD
Everolimus—Pain—Hydrocortisone—asthma	3.35e-05	0.000106	CcSEcCtD
Everolimus—Oedema—Betamethasone—asthma	3.35e-05	0.000105	CcSEcCtD
Everolimus—Oedema—Dexamethasone—asthma	3.35e-05	0.000105	CcSEcCtD
Everolimus—MTOR—Immune System—ITPR1—asthma	3.34e-05	0.000258	CbGpPWpGaD
Everolimus—Insomnia—Triamcinolone—asthma	3.34e-05	0.000105	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—CCR3—asthma	3.33e-05	0.000257	CbGpPWpGaD
Everolimus—Insomnia—Methylprednisolone—asthma	3.33e-05	0.000105	CcSEcCtD
Everolimus—Infection—Dexamethasone—asthma	3.33e-05	0.000105	CcSEcCtD
Everolimus—Infection—Betamethasone—asthma	3.33e-05	0.000105	CcSEcCtD
Everolimus—Ill-defined disorder—Prednisone—asthma	3.31e-05	0.000104	CcSEcCtD
Everolimus—Paraesthesia—Triamcinolone—asthma	3.31e-05	0.000104	CcSEcCtD
Everolimus—FKBP1A—Disease—SERPINE1—asthma	3.31e-05	0.000255	CbGpPWpGaD
Everolimus—MTOR—Immune System—HLA-DQB1—asthma	3.31e-05	0.000255	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PPP2CA—asthma	3.31e-05	0.000255	CbGpPWpGaD
Everolimus—Feeling abnormal—Prednisolone—asthma	3.31e-05	0.000104	CcSEcCtD
Everolimus—Paraesthesia—Methylprednisolone—asthma	3.31e-05	0.000104	CcSEcCtD
Everolimus—Anaemia—Prednisone—asthma	3.3e-05	0.000104	CcSEcCtD
Everolimus—Shock—Betamethasone—asthma	3.29e-05	0.000104	CcSEcCtD
Everolimus—Shock—Dexamethasone—asthma	3.29e-05	0.000104	CcSEcCtD
Everolimus—Dyspnoea—Triamcinolone—asthma	3.29e-05	0.000104	CcSEcCtD
Everolimus—Nervous system disorder—Betamethasone—asthma	3.28e-05	0.000103	CcSEcCtD
Everolimus—Nervous system disorder—Dexamethasone—asthma	3.28e-05	0.000103	CcSEcCtD
Everolimus—Agitation—Prednisone—asthma	3.28e-05	0.000103	CcSEcCtD
Everolimus—Thrombocytopenia—Dexamethasone—asthma	3.28e-05	0.000103	CcSEcCtD
Everolimus—Thrombocytopenia—Betamethasone—asthma	3.28e-05	0.000103	CcSEcCtD
Everolimus—Tachycardia—Betamethasone—asthma	3.27e-05	0.000103	CcSEcCtD
Everolimus—Tachycardia—Dexamethasone—asthma	3.27e-05	0.000103	CcSEcCtD
Everolimus—Angioedema—Prednisone—asthma	3.26e-05	0.000103	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—NPY—asthma	3.25e-05	0.00025	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CCR5—asthma	3.25e-05	0.00025	CbGpPWpGaD
Everolimus—Dyspepsia—Triamcinolone—asthma	3.25e-05	0.000102	CcSEcCtD
Everolimus—Dyspepsia—Methylprednisolone—asthma	3.24e-05	0.000102	CcSEcCtD
Everolimus—Hyperhidrosis—Dexamethasone—asthma	3.24e-05	0.000102	CcSEcCtD
Everolimus—Hyperhidrosis—Betamethasone—asthma	3.24e-05	0.000102	CcSEcCtD
Everolimus—Feeling abnormal—Hydrocortisone—asthma	3.23e-05	0.000102	CcSEcCtD
Everolimus—Malaise—Prednisone—asthma	3.22e-05	0.000101	CcSEcCtD
Everolimus—Gastrointestinal pain—Hydrocortisone—asthma	3.2e-05	0.000101	CcSEcCtD
Everolimus—Syncope—Prednisone—asthma	3.2e-05	0.000101	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—IL2RA—asthma	3.2e-05	0.000247	CbGpPWpGaD
Everolimus—FKBP1A—Disease—RHOA—asthma	3.19e-05	0.000246	CbGpPWpGaD
Everolimus—Anorexia—Dexamethasone—asthma	3.19e-05	0.0001	CcSEcCtD
Everolimus—Anorexia—Betamethasone—asthma	3.19e-05	0.0001	CcSEcCtD
Everolimus—MTOR—Immune System—CD86—asthma	3.19e-05	0.000245	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—BCL2—asthma	3.18e-05	0.000245	CbGpPWpGaD
Everolimus—Fatigue—Triamcinolone—asthma	3.18e-05	0.0001	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—C3—asthma	3.17e-05	0.000244	CbGpPWpGaD
Everolimus—Fatigue—Methylprednisolone—asthma	3.17e-05	9.99e-05	CcSEcCtD
Everolimus—FKBP1A—Disease—NOS3—asthma	3.16e-05	0.000243	CbGpPWpGaD
Everolimus—Pain—Triamcinolone—asthma	3.15e-05	9.93e-05	CcSEcCtD
Everolimus—Loss of consciousness—Prednisone—asthma	3.14e-05	9.89e-05	CcSEcCtD
Everolimus—MTOR—Immune System—IL18—asthma	3.14e-05	0.000242	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—AGTR2—asthma	3.13e-05	0.000241	CbGpPWpGaD
Everolimus—Hypotension—Betamethasone—asthma	3.13e-05	9.85e-05	CcSEcCtD
Everolimus—Hypotension—Dexamethasone—asthma	3.13e-05	9.85e-05	CcSEcCtD
Everolimus—MTOR—Immune System—CD40LG—asthma	3.12e-05	0.000241	CbGpPWpGaD
Everolimus—Body temperature increased—Hydrocortisone—asthma	3.1e-05	9.75e-05	CcSEcCtD
Everolimus—Abdominal pain—Hydrocortisone—asthma	3.1e-05	9.75e-05	CcSEcCtD
Everolimus—Convulsion—Prednisone—asthma	3.09e-05	9.75e-05	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—PDGFB—asthma	3.09e-05	0.000238	CbGpPWpGaD
Everolimus—MTOR—Immune System—CD8A—asthma	3.09e-05	0.000238	CbGpPWpGaD
Everolimus—MTOR—Immune System—CSF2—asthma	3.09e-05	0.000238	CbGpPWpGaD
Everolimus—MTOR—Disease—ITPR1—asthma	3.09e-05	0.000238	CbGpPWpGaD
Everolimus—Hypertension—Prednisone—asthma	3.08e-05	9.71e-05	CcSEcCtD
Everolimus—MTOR—Cellular responses to stress—IL6—asthma	3.08e-05	0.000237	CbGpPWpGaD
Everolimus—Musculoskeletal discomfort—Betamethasone—asthma	3.05e-05	9.6e-05	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Dexamethasone—asthma	3.05e-05	9.6e-05	CcSEcCtD
Everolimus—MTOR—Innate Immune System—CD4—asthma	3.05e-05	0.000235	CbGpPWpGaD
Everolimus—Myalgia—Prednisone—asthma	3.04e-05	9.58e-05	CcSEcCtD
Everolimus—Arthralgia—Prednisone—asthma	3.04e-05	9.58e-05	CcSEcCtD
Everolimus—Feeling abnormal—Triamcinolone—asthma	3.04e-05	9.57e-05	CcSEcCtD
Everolimus—Feeling abnormal—Methylprednisolone—asthma	3.03e-05	9.55e-05	CcSEcCtD
Everolimus—Anxiety—Prednisone—asthma	3.03e-05	9.54e-05	CcSEcCtD
Everolimus—Insomnia—Dexamethasone—asthma	3.03e-05	9.53e-05	CcSEcCtD
Everolimus—Insomnia—Betamethasone—asthma	3.03e-05	9.53e-05	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Prednisone—asthma	3.02e-05	9.51e-05	CcSEcCtD
Everolimus—MTOR—Immune System—AGER—asthma	3.01e-05	0.000232	CbGpPWpGaD
Everolimus—Gastrointestinal pain—Methylprednisolone—asthma	3.01e-05	9.48e-05	CcSEcCtD
Everolimus—Paraesthesia—Betamethasone—asthma	3.01e-05	9.47e-05	CcSEcCtD
Everolimus—Paraesthesia—Dexamethasone—asthma	3.01e-05	9.47e-05	CcSEcCtD
Everolimus—Discomfort—Prednisone—asthma	3e-05	9.46e-05	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—EDNRB—asthma	3e-05	0.000231	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TAC1—asthma	2.97e-05	0.000229	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NPS—asthma	2.97e-05	0.000229	CbGpPWpGaD
Everolimus—Hypersensitivity—Prednisolone—asthma	2.96e-05	9.31e-05	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—LEP—asthma	2.95e-05	0.000228	CbGpPWpGaD
Everolimus—Dyspepsia—Betamethasone—asthma	2.95e-05	9.28e-05	CcSEcCtD
Everolimus—Dyspepsia—Dexamethasone—asthma	2.95e-05	9.28e-05	CcSEcCtD
Everolimus—MTOR—Disease—CD86—asthma	2.94e-05	0.000227	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CD4—asthma	2.92e-05	0.000225	CbGpPWpGaD
Everolimus—Body temperature increased—Triamcinolone—asthma	2.92e-05	9.18e-05	CcSEcCtD
Everolimus—Oedema—Prednisone—asthma	2.92e-05	9.18e-05	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—CXCR3—asthma	2.91e-05	0.000224	CbGpPWpGaD
Everolimus—FKBP1A—Disease—CD4—asthma	2.91e-05	0.000224	CbGpPWpGaD
Everolimus—Abdominal pain—Methylprednisolone—asthma	2.91e-05	9.16e-05	CcSEcCtD
Everolimus—Decreased appetite—Betamethasone—asthma	2.91e-05	9.16e-05	CcSEcCtD
Everolimus—Decreased appetite—Dexamethasone—asthma	2.91e-05	9.16e-05	CcSEcCtD
Everolimus—Infection—Prednisone—asthma	2.9e-05	9.12e-05	CcSEcCtD
Everolimus—FKBP1A—Disease—PTGS2—asthma	2.89e-05	0.000223	CbGpPWpGaD
Everolimus—Gastrointestinal disorder—Betamethasone—asthma	2.89e-05	9.1e-05	CcSEcCtD
Everolimus—Gastrointestinal disorder—Dexamethasone—asthma	2.89e-05	9.1e-05	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—IL6—asthma	2.89e-05	0.000222	CbGpPWpGaD
Everolimus—Hypersensitivity—Hydrocortisone—asthma	2.89e-05	9.09e-05	CcSEcCtD
Everolimus—Fatigue—Dexamethasone—asthma	2.89e-05	9.09e-05	CcSEcCtD
Everolimus—Fatigue—Betamethasone—asthma	2.89e-05	9.09e-05	CcSEcCtD
Everolimus—MTOR—Immune System—PPP2CA—asthma	2.88e-05	0.000222	CbGpPWpGaD
Everolimus—Shock—Prednisone—asthma	2.87e-05	9.03e-05	CcSEcCtD
Everolimus—Pain—Dexamethasone—asthma	2.86e-05	9.01e-05	CcSEcCtD
Everolimus—Pain—Betamethasone—asthma	2.86e-05	9.01e-05	CcSEcCtD
Everolimus—Nervous system disorder—Prednisone—asthma	2.86e-05	9e-05	CcSEcCtD
Everolimus—Tachycardia—Prednisone—asthma	2.84e-05	8.96e-05	CcSEcCtD
Everolimus—Skin disorder—Prednisone—asthma	2.83e-05	8.92e-05	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—CYBA—asthma	2.82e-05	0.000217	CbGpPWpGaD
Everolimus—Hyperhidrosis—Prednisone—asthma	2.82e-05	8.87e-05	CcSEcCtD
Everolimus—Asthenia—Hydrocortisone—asthma	2.81e-05	8.85e-05	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—FN1—asthma	2.79e-05	0.000215	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL2RA—asthma	2.78e-05	0.000214	CbGpPWpGaD
Everolimus—Anorexia—Prednisone—asthma	2.78e-05	8.75e-05	CcSEcCtD
Everolimus—MTOR—Disease—SMAD3—asthma	2.78e-05	0.000214	CbGpPWpGaD
Everolimus—Pruritus—Hydrocortisone—asthma	2.77e-05	8.73e-05	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—PARP1—asthma	2.76e-05	0.000213	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IL5—asthma	2.76e-05	0.000213	CbGpPWpGaD
Everolimus—MTOR—Immune System—C3—asthma	2.76e-05	0.000213	CbGpPWpGaD
Everolimus—Feeling abnormal—Betamethasone—asthma	2.76e-05	8.69e-05	CcSEcCtD
Everolimus—Feeling abnormal—Dexamethasone—asthma	2.76e-05	8.69e-05	CcSEcCtD
Everolimus—Gastrointestinal pain—Betamethasone—asthma	2.74e-05	8.62e-05	CcSEcCtD
Everolimus—Gastrointestinal pain—Dexamethasone—asthma	2.74e-05	8.62e-05	CcSEcCtD
Everolimus—Hypersensitivity—Triamcinolone—asthma	2.72e-05	8.56e-05	CcSEcCtD
Everolimus—Hypersensitivity—Methylprednisolone—asthma	2.71e-05	8.54e-05	CcSEcCtD
Everolimus—MTOR—Immune System—PDGFB—asthma	2.69e-05	0.000207	CbGpPWpGaD
Everolimus—Diarrhoea—Hydrocortisone—asthma	2.68e-05	8.44e-05	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—BDKRB2—asthma	2.67e-05	0.000205	CbGpPWpGaD
Everolimus—MTOR—Disease—PPP2CA—asthma	2.66e-05	0.000205	CbGpPWpGaD
Everolimus—Musculoskeletal discomfort—Prednisone—asthma	2.66e-05	8.36e-05	CcSEcCtD
Everolimus—Dizziness—Prednisolone—asthma	2.65e-05	8.35e-05	CcSEcCtD
Everolimus—CYP3A4—Biological oxidations—POMC—asthma	2.65e-05	0.000204	CbGpPWpGaD
Everolimus—Asthenia—Triamcinolone—asthma	2.65e-05	8.34e-05	CcSEcCtD
Everolimus—Body temperature increased—Dexamethasone—asthma	2.65e-05	8.33e-05	CcSEcCtD
Everolimus—Abdominal pain—Betamethasone—asthma	2.65e-05	8.33e-05	CcSEcCtD
Everolimus—Abdominal pain—Dexamethasone—asthma	2.65e-05	8.33e-05	CcSEcCtD
Everolimus—Body temperature increased—Betamethasone—asthma	2.65e-05	8.33e-05	CcSEcCtD
Everolimus—Asthenia—Methylprednisolone—asthma	2.64e-05	8.32e-05	CcSEcCtD
Everolimus—MTOR—Innate Immune System—PTEN—asthma	2.64e-05	0.000203	CbGpPWpGaD
Everolimus—Insomnia—Prednisone—asthma	2.64e-05	8.3e-05	CcSEcCtD
Everolimus—MTOR—Immune System—CRP—asthma	2.63e-05	0.000202	CbGpPWpGaD
Everolimus—Paraesthesia—Prednisone—asthma	2.62e-05	8.24e-05	CcSEcCtD
Everolimus—Pruritus—Triamcinolone—asthma	2.61e-05	8.22e-05	CcSEcCtD
Everolimus—MTOR—Disease—CCR5—asthma	2.61e-05	0.000201	CbGpPWpGaD
Everolimus—Pruritus—Methylprednisolone—asthma	2.6e-05	8.2e-05	CcSEcCtD
Everolimus—Dizziness—Hydrocortisone—asthma	2.59e-05	8.16e-05	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—ADCY2—asthma	2.58e-05	0.000199	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IL3—asthma	2.57e-05	0.000198	CbGpPWpGaD
Everolimus—Dyspepsia—Prednisone—asthma	2.57e-05	8.08e-05	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—POMC—asthma	2.54e-05	0.000196	CbGpPWpGaD
Everolimus—Decreased appetite—Prednisone—asthma	2.53e-05	7.98e-05	CcSEcCtD
Everolimus—MTOR—Adaptive Immune System—PTEN—asthma	2.53e-05	0.000195	CbGpPWpGaD
Everolimus—Rash—Prednisolone—asthma	2.53e-05	7.97e-05	CcSEcCtD
Everolimus—Dermatitis—Prednisolone—asthma	2.53e-05	7.96e-05	CcSEcCtD
Everolimus—FKBP1A—Disease—PTEN—asthma	2.52e-05	0.000194	CbGpPWpGaD
Everolimus—Diarrhoea—Methylprednisolone—asthma	2.52e-05	7.93e-05	CcSEcCtD
Everolimus—MTOR—Immune System—TLR4—asthma	2.52e-05	0.000194	CbGpPWpGaD
Everolimus—MTOR—Immune System—HLA-DRB1—asthma	2.52e-05	0.000194	CbGpPWpGaD
Everolimus—Fatigue—Prednisone—asthma	2.51e-05	7.91e-05	CcSEcCtD
Everolimus—Headache—Prednisolone—asthma	2.51e-05	7.91e-05	CcSEcCtD
Everolimus—CYP3A4—Metabolism—LTC4S—asthma	2.5e-05	0.000192	CbGpPWpGaD
Everolimus—Constipation—Prednisone—asthma	2.49e-05	7.85e-05	CcSEcCtD
Everolimus—Vomiting—Hydrocortisone—asthma	2.49e-05	7.84e-05	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—CCL2—asthma	2.48e-05	0.000191	CbGpPWpGaD
Everolimus—MTOR—Disease—PDGFB—asthma	2.48e-05	0.000191	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IL6R—asthma	2.48e-05	0.000191	CbGpPWpGaD
Everolimus—Rash—Hydrocortisone—asthma	2.47e-05	7.78e-05	CcSEcCtD
Everolimus—Dermatitis—Hydrocortisone—asthma	2.47e-05	7.77e-05	CcSEcCtD
Everolimus—Headache—Hydrocortisone—asthma	2.45e-05	7.73e-05	CcSEcCtD
Everolimus—Dizziness—Triamcinolone—asthma	2.44e-05	7.68e-05	CcSEcCtD
Everolimus—Dizziness—Methylprednisolone—asthma	2.43e-05	7.67e-05	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—KNG1—asthma	2.42e-05	0.000187	CbGpPWpGaD
Everolimus—MTOR—Immune System—ICAM1—asthma	2.41e-05	0.000186	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—AGTR1—asthma	2.41e-05	0.000186	CbGpPWpGaD
Everolimus—Feeling abnormal—Prednisone—asthma	2.4e-05	7.56e-05	CcSEcCtD
Everolimus—Asthenia—Betamethasone—asthma	2.4e-05	7.56e-05	CcSEcCtD
Everolimus—Asthenia—Dexamethasone—asthma	2.4e-05	7.56e-05	CcSEcCtD
Everolimus—Gastrointestinal pain—Prednisone—asthma	2.38e-05	7.51e-05	CcSEcCtD
Everolimus—Nausea—Prednisolone—asthma	2.38e-05	7.5e-05	CcSEcCtD
Everolimus—Pruritus—Betamethasone—asthma	2.37e-05	7.46e-05	CcSEcCtD
Everolimus—Pruritus—Dexamethasone—asthma	2.37e-05	7.46e-05	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—CXCL10—asthma	2.36e-05	0.000181	CbGpPWpGaD
Everolimus—Vomiting—Triamcinolone—asthma	2.35e-05	7.39e-05	CcSEcCtD
Everolimus—Vomiting—Methylprednisolone—asthma	2.34e-05	7.37e-05	CcSEcCtD
Everolimus—Nausea—Hydrocortisone—asthma	2.33e-05	7.33e-05	CcSEcCtD
Everolimus—Rash—Triamcinolone—asthma	2.33e-05	7.33e-05	CcSEcCtD
Everolimus—Dermatitis—Triamcinolone—asthma	2.32e-05	7.32e-05	CcSEcCtD
Everolimus—Rash—Methylprednisolone—asthma	2.32e-05	7.31e-05	CcSEcCtD
Everolimus—Dermatitis—Methylprednisolone—asthma	2.32e-05	7.3e-05	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—SERPINE1—asthma	2.32e-05	0.000179	CbGpPWpGaD
Everolimus—Headache—Triamcinolone—asthma	2.31e-05	7.28e-05	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—NTRK1—asthma	2.31e-05	0.000178	CbGpPWpGaD
Everolimus—Headache—Methylprednisolone—asthma	2.31e-05	7.26e-05	CcSEcCtD
Everolimus—Body temperature increased—Prednisone—asthma	2.3e-05	7.26e-05	CcSEcCtD
Everolimus—Abdominal pain—Prednisone—asthma	2.3e-05	7.26e-05	CcSEcCtD
Everolimus—Diarrhoea—Betamethasone—asthma	2.29e-05	7.21e-05	CcSEcCtD
Everolimus—Diarrhoea—Dexamethasone—asthma	2.29e-05	7.21e-05	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—ADRB2—asthma	2.29e-05	0.000176	CbGpPWpGaD
Everolimus—FKBP1A—Disease—STAT3—asthma	2.25e-05	0.000174	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—RHOA—asthma	2.24e-05	0.000172	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—NOS3—asthma	2.21e-05	0.00017	CbGpPWpGaD
Everolimus—Dizziness—Dexamethasone—asthma	2.21e-05	6.97e-05	CcSEcCtD
Everolimus—Dizziness—Betamethasone—asthma	2.21e-05	6.97e-05	CcSEcCtD
Everolimus—MTOR—Disease—NOS2—asthma	2.21e-05	0.00017	CbGpPWpGaD
Everolimus—Nausea—Triamcinolone—asthma	2.19e-05	6.9e-05	CcSEcCtD
Everolimus—Nausea—Methylprednisolone—asthma	2.19e-05	6.89e-05	CcSEcCtD
Everolimus—CYP3A4—Metabolism—LTA4H—asthma	2.17e-05	0.000167	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ITPR1—asthma	2.16e-05	0.000167	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL6R—asthma	2.15e-05	0.000166	CbGpPWpGaD
Everolimus—Hypersensitivity—Prednisone—asthma	2.15e-05	6.76e-05	CcSEcCtD
Everolimus—MTOR—Innate Immune System—EGFR—asthma	2.14e-05	0.000165	CbGpPWpGaD
Everolimus—Vomiting—Dexamethasone—asthma	2.13e-05	6.7e-05	CcSEcCtD
Everolimus—Vomiting—Betamethasone—asthma	2.13e-05	6.7e-05	CcSEcCtD
Everolimus—Rash—Dexamethasone—asthma	2.11e-05	6.65e-05	CcSEcCtD
Everolimus—Rash—Betamethasone—asthma	2.11e-05	6.65e-05	CcSEcCtD
Everolimus—Dermatitis—Betamethasone—asthma	2.11e-05	6.64e-05	CcSEcCtD
Everolimus—Dermatitis—Dexamethasone—asthma	2.11e-05	6.64e-05	CcSEcCtD
Everolimus—Headache—Dexamethasone—asthma	2.1e-05	6.6e-05	CcSEcCtD
Everolimus—Headache—Betamethasone—asthma	2.1e-05	6.6e-05	CcSEcCtD
Everolimus—Asthenia—Prednisone—asthma	2.09e-05	6.59e-05	CcSEcCtD
Everolimus—FKBP1A—Disease—TGFB1—asthma	2.09e-05	0.000161	CbGpPWpGaD
Everolimus—Pruritus—Prednisone—asthma	2.06e-05	6.49e-05	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—CD86—asthma	2.06e-05	0.000159	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—EGFR—asthma	2.06e-05	0.000159	CbGpPWpGaD
Everolimus—FKBP1A—Disease—EGFR—asthma	2.05e-05	0.000158	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—EDN1—asthma	2.04e-05	0.000157	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CCL5—asthma	2.03e-05	0.000156	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PLA2G4A—asthma	2.02e-05	0.000156	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CSF2—asthma	2e-05	0.000154	CbGpPWpGaD
Everolimus—Diarrhoea—Prednisone—asthma	1.99e-05	6.28e-05	CcSEcCtD
Everolimus—MTOR—Disease—IL6R—asthma	1.99e-05	0.000153	CbGpPWpGaD
Everolimus—Nausea—Betamethasone—asthma	1.99e-05	6.26e-05	CcSEcCtD
Everolimus—Nausea—Dexamethasone—asthma	1.99e-05	6.26e-05	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—CXCL8—asthma	1.96e-05	0.000151	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—SMAD3—asthma	1.94e-05	0.00015	CbGpPWpGaD
Everolimus—Dizziness—Prednisone—asthma	1.93e-05	6.07e-05	CcSEcCtD
Everolimus—CYP3A4—Metabolism—ARG1—asthma	1.89e-05	0.000146	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IL2—asthma	1.88e-05	0.000145	CbGpPWpGaD
Everolimus—MTOR—Disease—SERPINE1—asthma	1.86e-05	0.000143	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PPP2CA—asthma	1.86e-05	0.000143	CbGpPWpGaD
Everolimus—MTOR—Immune System—BCL2—asthma	1.85e-05	0.000143	CbGpPWpGaD
Everolimus—Vomiting—Prednisone—asthma	1.85e-05	5.84e-05	CcSEcCtD
Everolimus—Rash—Prednisone—asthma	1.84e-05	5.79e-05	CcSEcCtD
Everolimus—MTOR—Immune System—IFNG—asthma	1.84e-05	0.000141	CbGpPWpGaD
Everolimus—Dermatitis—Prednisone—asthma	1.84e-05	5.78e-05	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—CCR5—asthma	1.83e-05	0.000141	CbGpPWpGaD
Everolimus—Headache—Prednisone—asthma	1.83e-05	5.75e-05	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—IL2RA—asthma	1.8e-05	0.000139	CbGpPWpGaD
Everolimus—MTOR—Disease—RHOA—asthma	1.8e-05	0.000138	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—C3—asthma	1.78e-05	0.000137	CbGpPWpGaD
Everolimus—MTOR—Disease—NOS3—asthma	1.78e-05	0.000137	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MMP9—asthma	1.78e-05	0.000137	CbGpPWpGaD
Everolimus—MTOR—Immune System—CD4—asthma	1.77e-05	0.000137	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PTEN—asthma	1.77e-05	0.000136	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PDGFB—asthma	1.74e-05	0.000134	CbGpPWpGaD
Everolimus—Nausea—Prednisone—asthma	1.73e-05	5.45e-05	CcSEcCtD
Everolimus—CYP3A4—Metabolism—ALDH7A1—asthma	1.71e-05	0.000132	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—LEP—asthma	1.66e-05	0.000128	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—IL6—asthma	1.65e-05	0.000127	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ARG2—asthma	1.64e-05	0.000126	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL1B—asthma	1.64e-05	0.000126	CbGpPWpGaD
Everolimus—MTOR—Disease—CD4—asthma	1.64e-05	0.000126	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL2—asthma	1.63e-05	0.000126	CbGpPWpGaD
Everolimus—MTOR—Disease—PTGS2—asthma	1.63e-05	0.000125	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—VEGFA—asthma	1.59e-05	0.000123	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—STAT3—asthma	1.58e-05	0.000122	CbGpPWpGaD
Everolimus—FKBP1A—Disease—IL6—asthma	1.58e-05	0.000121	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—FN1—asthma	1.57e-05	0.000121	CbGpPWpGaD
Everolimus—MTOR—Immune System—PTEN—asthma	1.54e-05	0.000118	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TGFB1—asthma	1.46e-05	0.000113	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—EGFR—asthma	1.44e-05	0.000111	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—POMC—asthma	1.43e-05	0.00011	CbGpPWpGaD
Everolimus—MTOR—Disease—PTEN—asthma	1.42e-05	0.000109	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CCL2—asthma	1.4e-05	0.000108	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IL6R—asthma	1.39e-05	0.000107	CbGpPWpGaD
Everolimus—MTOR—Immune System—STAT3—asthma	1.37e-05	0.000106	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ALOX5AP—asthma	1.36e-05	0.000105	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ALOX15—asthma	1.36e-05	0.000105	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—SERPINE1—asthma	1.3e-05	0.0001	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CHAT—asthma	1.3e-05	9.99e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—STAT3—asthma	1.27e-05	9.77e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—RHOA—asthma	1.26e-05	9.69e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—EGFR—asthma	1.25e-05	9.62e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NOS3—asthma	1.24e-05	9.59e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—TGFB1—asthma	1.18e-05	9.05e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ALOX5—asthma	1.16e-05	8.91e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—EGFR—asthma	1.15e-05	8.88e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CXCL8—asthma	1.1e-05	8.51e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IL6—asthma	1.1e-05	8.5e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CARM1—asthma	1.1e-05	8.5e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—DCN—asthma	1.09e-05	8.37e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ALDH2—asthma	1.06e-05	8.14e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IL2—asthma	1.06e-05	8.13e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GSTT1—asthma	1.01e-05	7.75e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MMP9—asthma	9.99e-06	7.69e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PTEN—asthma	9.93e-06	7.65e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL6—asthma	9.59e-06	7.39e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—VEGFA—asthma	8.97e-06	6.91e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—STAT3—asthma	8.88e-06	6.84e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—IL6—asthma	8.86e-06	6.82e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—NQO1—asthma	8.36e-06	6.44e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TGFB1—asthma	8.23e-06	6.34e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ADCY2—asthma	8.18e-06	6.3e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—EGFR—asthma	8.07e-06	6.22e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GSTP1—asthma	6.97e-06	5.37e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—HMOX1—asthma	6.88e-06	5.3e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ITPR1—asthma	6.86e-06	5.28e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CAT—asthma	6.78e-06	5.23e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GSTM1—asthma	6.41e-06	4.93e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PLA2G4A—asthma	6.41e-06	4.93e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IL6—asthma	6.2e-06	4.78e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PPP2CA—asthma	5.9e-06	4.54e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—POMC—asthma	4.53e-06	3.49e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ALB—asthma	4.13e-06	3.18e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—NOS3—asthma	3.95e-06	3.04e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PTGS2—asthma	3.61e-06	2.78e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PTEN—asthma	3.15e-06	2.43e-05	CbGpPWpGaD
